BMC cancer [electronic resource]
BMC Cancer 2021 Nov 25; 21(1):1273
PURPOSE: Large-panel genomic tumor testing (GTT) is an emerging technology with great promise but uncertain clinical value. Previous research has documented variability in academic oncologists' perceptions and use of GTT, but little is known about community oncologists' perceptions of GTT and how perceptions relate to clinicians' intentions to use GTT.
METHODS: Community oncology physicians (N = 58) participating in a statewide initiative aimed at improving access to large-panel GTT completed surveys assessing their confidence in using GTT, attitudes regarding the value of GTT, perceptions of barriers to GTT implementation, and future intentions to use GTTs. Descriptive and multivariable regression analyses were conducted to characterize these perceptions and to explore the relationships between them.
RESULTS: There was substantial variability in clinicians' perceptions of GTT. Clinicians generally had moderate confidence in their ability to use GTT, but lower confidence in patients' ability to understand test results and access targeted treatment. Clinicians had positive attitudes regarding the value of GTT. Clinicians' future intentions to use GTT were associated with greater confidence in using GTT and greater perceived barriers to implementing GTT, but not with attitudes about the value of GTT.
CONCLUSIONS: Community oncologists' perceptions of large-panel genomic tumor testing are variable, and their future intentions to use GTT are associated with both their confidence in and perceived barriers to its use, but not with their attitudes towards GTT. More research is needed to understand other factors that determine how oncologists perceive and use GTT in clinical practice.
Anderson, Eric C; Hinton, Alexandra C; Lary, Christine W; Fenton, Anny T H R; Antov, Andrey; Edelman, Emily A; Helbig, Petra; Reed, Kate; Miesfeldt, Susan; Thomas, Christian A; Hall, Michael J; Roberts, J Scott; Rueter, Jens; Han, Paul K J; and Group, MCGI Working, "Community oncologists' perceptions and utilization of large-panel genomic tumor testing." (2021). Faculty Research 2021. 244.